These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 25023888)

  • 1. GLP-1 receptor agonist liraglutide reverses long-term atypical antipsychotic treatment associated behavioral depression and metabolic abnormalities in rats.
    Sharma AN; Ligade SS; Sharma JN; Shukla P; Elased KM; Lucot JB
    Metab Brain Dis; 2015 Apr; 30(2):519-27. PubMed ID: 25023888
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Glucagon-like peptide-1 receptor agonists for antipsychotic-associated cardio-metabolic risk factors: A systematic review and individual participant data meta-analysis.
    Siskind D; Hahn M; Correll CU; Fink-Jensen A; Russell AW; Bak N; Broberg BV; Larsen J; Ishøy PL; Vilsbøll T; Knop FK; Kisely S; Ebdrup BH
    Diabetes Obes Metab; 2019 Feb; 21(2):293-302. PubMed ID: 30187620
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Does a GLP-1 receptor agonist change glucose tolerance in patients treated with antipsychotic medications? Design of a randomised, double-blinded, placebo-controlled clinical trial.
    Larsen JR; Vedtofte L; Holst JJ; Oturai P; Kjær A; Correll CU; Vilsbøll T; Fink-Jensen A
    BMJ Open; 2014 Mar; 4(3):e004227. PubMed ID: 24667381
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of liraglutide on neural and peripheral markers of metabolic function during antipsychotic treatment in rats.
    Babic I; Sellers D; Else PL; Nealon J; Osborne AL; Pai N; Weston-Green K
    J Psychopharmacol; 2021 Mar; 35(3):284-302. PubMed ID: 33570012
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Potent synergistic effects of dulaglutide and food restriction in prevention of olanzapine-induced metabolic adverse effects in a rodent model.
    Horska K; Kucera J; Drazanova E; Kuzminova G; Amchova P; Hrickova M; Ruda-Kucerova J; Skrede S
    Biomed Pharmacother; 2024 Jul; 176():116763. PubMed ID: 38805968
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Liraglutide prevents metabolic side-effects and improves recognition and working memory during antipsychotic treatment in rats.
    Babic I; Gorak A; Engel M; Sellers D; Else P; Osborne AL; Pai N; Huang XF; Nealon J; Weston-Green K
    J Psychopharmacol; 2018 May; 32(5):578-590. PubMed ID: 29493378
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The once-daily human GLP-1 analog, liraglutide, reduces olanzapine-induced weight gain and glucose intolerance.
    Lykkegaard K; Larsen PJ; Vrang N; Bock C; Bock T; Knudsen LB
    Schizophr Res; 2008 Aug; 103(1-3):94-103. PubMed ID: 18579346
    [TBL] [Abstract][Full Text] [Related]  

  • 8. One-year follow-up on liraglutide treatment for prediabetes and overweight/obesity in clozapine- or olanzapine-treated patients.
    Svensson CK; Larsen JR; Vedtofte L; Jakobsen MSL; Jespersen HR; Jakobsen MI; Koyuncu K; Schjerning O; Nielsen J; Ekstrøm CT; Correll CU; Vilsbøll T; Fink-Jensen A
    Acta Psychiatr Scand; 2019 Jan; 139(1):26-36. PubMed ID: 30374965
    [TBL] [Abstract][Full Text] [Related]  

  • 9. GLP1 receptor agonism protects against acute olanzapine-induced hyperglycemia.
    Medak KD; Shamshoum H; Peppler WT; Wright DC
    Am J Physiol Endocrinol Metab; 2020 Dec; 319(6):E1101-E1111. PubMed ID: 33017220
    [TBL] [Abstract][Full Text] [Related]  

  • 10. H3 histamine receptor antagonist pitolisant reverses some subchronic disturbances induced by olanzapine in mice.
    Dudek M; Kuder K; Kołaczkowski M; Olczyk A; Żmudzka E; Rak A; Bednarski M; Pytka K; Sapa J; Kieć-Kononowicz K
    Metab Brain Dis; 2016 Oct; 31(5):1023-9. PubMed ID: 27216278
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A comparison of drug effects in latent inhibition and the forced swim test differentiates between the typical antipsychotic haloperidol, the atypical antipsychotics clozapine and olanzapine, and the antidepressants imipramine and paroxetine.
    Weiner I; Schiller D; Gaisler-Salomon I; Green A; Joel D
    Behav Pharmacol; 2003 May; 14(3):215-22. PubMed ID: 12799523
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The distinct effects of subchronic antipsychotic drug treatment on macronutrient selection, body weight, adiposity, and metabolism in female rats.
    Fell MJ; Anjum N; Dickinson K; Marshall KM; Peltola LM; Vickers S; Cheetham S; Neill JC
    Psychopharmacology (Berl); 2007 Oct; 194(2):221-31. PubMed ID: 17581744
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metformin attenuates antipsychotic-induced metabolic dysfunctions in MK801-induced schizophrenia-like rats.
    Luo C; Wang X; Mao X; Huang H; Liu Y; Zhao J; Zhou H; Liu Z; Li X
    Psychopharmacology (Berl); 2020 Aug; 237(8):2257-2277. PubMed ID: 32588080
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The dual amylin and calcitonin receptor agonist KBP-089 and the GLP-1 receptor agonist liraglutide act complimentarily on body weight reduction and metabolic profile.
    Larsen AT; Gydesen S; Sonne N; Karsdal MA; Henriksen K
    BMC Endocr Disord; 2021 Jan; 21(1):10. PubMed ID: 33413317
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Liraglutide prevents cognitive decline in a rat model of streptozotocin-induced diabetes independently from its peripheral metabolic effects.
    Palleria C; Leo A; Andreozzi F; Citraro R; Iannone M; Spiga R; Sesti G; Constanti A; De Sarro G; Arturi F; Russo E
    Behav Brain Res; 2017 Mar; 321():157-169. PubMed ID: 28062257
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Antipsychotics in bipolar disorders].
    Vacheron-Trystram MN; Braitman A; Cheref S; Auffray L
    Encephale; 2004; 30(5):417-24. PubMed ID: 15627046
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization of liraglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, in rat partial and full nigral 6-hydroxydopamine lesion models of Parkinson's disease.
    Hansen HH; Fabricius K; Barkholt P; Mikkelsen JD; Jelsing J; Pyke C; Knudsen LB; Vrang N
    Brain Res; 2016 Sep; 1646():354-365. PubMed ID: 27233809
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Glucagon-like peptide-1 receptor agonist treatment of high carbohydrate intake-induced metabolic syndrome provides pleiotropic effects on cardiac dysfunction through alleviations in electrical and intracellular Ca
    Durak A; Akkus E; Canpolat AG; Tuncay E; Corapcioglu D; Turan B
    Clin Exp Pharmacol Physiol; 2022 Jan; 49(1):46-59. PubMed ID: 34519087
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of nausea in food intake and body weight suppression by peripheral GLP-1 receptor agonists, exendin-4 and liraglutide.
    Kanoski SE; Rupprecht LE; Fortin SM; De Jonghe BC; Hayes MR
    Neuropharmacology; 2012 Apr; 62(5-6):1916-27. PubMed ID: 22227019
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Olanzapine reduced brown adipose tissue thermogenesis and locomotor activity in female rats.
    Zhang Q; Lian J; He M; Deng C; Wang H; Huang XF
    Prog Neuropsychopharmacol Biol Psychiatry; 2014 Jun; 51():172-80. PubMed ID: 24548587
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.